Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GH NYSE:HIMS NASDAQ:NAKA NASDAQ:RDNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHGuardant Health$67.42+4.6%$51.69$20.14▼$67.51$8.41B1.452.80 million shs2.86 million shsHIMSHims & Hers Health$42.36-4.0%$49.98$13.47▼$72.98$9.57B2.1429.42 million shs16.08 million shsNAKAKindlyMD$5.44-8.3%$11.05$0.65▼$34.77$2.05B34.05948,295 shs1.86 million shsRDNTRadNet$71.760.0%$59.87$45.00▼$93.65$5.52B1.541.05 million shs627,715 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHGuardant Health0.00%+9.80%+62.77%+60.14%+163.57%HIMSHims & Hers Health0.00%-4.87%-32.30%-25.24%+187.58%NAKAKindlyMD0.00%-46.30%-14.33%+543,999,900.00%+543,999,900.00%RDNTRadNet0.00%+2.37%+31.21%+23.17%+8.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGHGuardant Health3.2053 of 5 stars1.52.00.04.43.52.50.6HIMSHims & Hers Health3.2064 of 5 stars2.03.00.00.02.63.33.1NAKAKindlyMDN/AN/AN/AN/AN/AN/AN/AN/ARDNTRadNet3.178 of 5 stars1.62.00.04.64.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHGuardant Health 3.06Buy$57.50-14.71% DownsideHIMSHims & Hers Health 1.92Reduce$38.92-8.13% DownsideNAKAKindlyMD 0.00N/AN/AN/ARDNTRadNet 3.25Buy$71.60-0.22% DownsideCurrent Analyst Ratings BreakdownLatest NAKA, HIMS, GH, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025HIMSHims & Hers HealthZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$48.00 ➝ $37.008/18/2025RDNTRadNetZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025RDNTRadNetRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$66.00 ➝ $75.008/11/2025RDNTRadNetMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOverweight8/5/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold7/31/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$57.00 ➝ $60.007/31/2025GHGuardant HealthRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$59.00 ➝ $61.007/17/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$45.00 ➝ $48.007/14/2025GHGuardant HealthEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/10/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$74.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHGuardant Health$828.85M10.14N/AN/A($1.13) per share-59.66HIMSHims & Hers Health$2.01B4.75$0.35 per share120.26$2.16 per share19.61NAKAKindlyMD$2.72M752.24N/AN/A$0.43 per share12.65RDNTRadNet$1.83B3.02$3.48 per share20.60$15.31 per share4.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHGuardant Health-$436.37M-$3.35N/AN/AN/A-49.93%N/A-28.95%11/5/2025 (Estimated)HIMSHims & Hers Health$126.04M$0.8052.9581.462.869.63%26.26%13.06%11/3/2025 (Estimated)NAKAKindlyMD-$3.62M-$0.86N/A∞N/A-244.00%-131.09%-106.04%N/ARDNTRadNet$2.79M-$0.20N/A135.40N/A-0.78%2.41%0.82%11/10/2025 (Estimated)Latest NAKA, HIMS, GH, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2025Q2 2025RDNTRadNet$0.17$0.31+$0.14$0.43$488.06 million$498.23 million8/5/2025Q2 2025NAKAKindlyMDN/A-$0.34N/A-$0.35N/A$0.41 million8/4/2025Q2 2025HIMSHims & Hers Health$0.18$0.17-$0.01$0.17$550.06 million$544.83 million7/30/2025Q2 2025GHGuardant Health-$0.52-$0.44+$0.08-$0.80$211.19 million$232.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHGuardant HealthN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/ANAKAKindlyMDN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHGuardant HealthN/A3.713.35HIMSHims & Hers Health1.724.984.46NAKAKindlyMDN/A13.0013.00RDNTRadNet0.912.002.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHGuardant Health92.60%HIMSHims & Hers Health63.52%NAKAKindlyMDN/ARDNTRadNet77.90%Insider OwnershipCompanyInsider OwnershipGHGuardant Health6.10%HIMSHims & Hers Health13.71%NAKAKindlyMD40.79%RDNTRadNet5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHGuardant Health2,021124.71 million117.10 millionNot OptionableHIMSHims & Hers Health1,637226.02 million185.99 millionOptionableNAKAKindlyMDN/A376.12 million222.70 millionN/ARDNTRadNet11,02176.92 million72.61 millionOptionableNAKA, HIMS, GH, and RDNT HeadlinesRecent News About These CompaniesKingdon Capital Management L.L.C. Invests $3.83 Million in RadNet, Inc. $RDNTSeptember 1 at 6:11 AM | marketbeat.comAmeriprise Financial Inc. Increases Stake in RadNet, Inc. $RDNTSeptember 1 at 4:00 AM | marketbeat.comNorthern Trust Corp Sells 25,927 Shares of RadNet, Inc. $RDNTSeptember 1 at 3:51 AM | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) Receives $71.60 Average Price Target from BrokeragesSeptember 1 at 2:01 AM | americanbankingnews.comExpect Equity LLC Acquires New Holdings in RadNet, Inc. $RDNTAugust 31 at 7:47 AM | marketbeat.comAlphaQuest LLC Increases Position in RadNet, Inc. $RDNTAugust 31 at 4:26 AM | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 31 at 3:30 AM | marketbeat.comRadNet (NASDAQ:RDNT) COO Sells $355,500.00 in StockAugust 30 at 7:18 AM | insidertrades.comHsbc Holdings PLC Sells 29,653 Shares of RadNet, Inc. $RDNTAugust 30 at 4:14 AM | marketbeat.comRadNet, Inc. $RDNT Holdings Lowered by Alpha Wave Global LPAugust 28, 2025 | marketbeat.comWellington Management Group LLP Acquires 7,872 Shares of RadNet, Inc. $RDNTAugust 28, 2025 | marketbeat.comRaymond James Financial Inc. Purchases 19,311 Shares of RadNet, Inc. $RDNTAugust 28, 2025 | marketbeat.comCoulda, Woulda, Shoulda: Are These 5 Stocks Too Overvalued to Buy Now?August 27, 2025 | kiplinger.comKRadNet, Inc. $RDNT Shares Sold by Axiom Investors LLC DEAugust 26, 2025 | marketbeat.comEntryPoint Capital LLC Makes New $206,000 Investment in RadNet, Inc. $RDNTAugust 26, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Grows Position in RadNet, Inc. $RDNTAugust 25, 2025 | marketbeat.comAdvantage Alpha Capital Partners LP Has $3.71 Million Stock Holdings in RadNet, Inc. $RDNTAugust 24, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Insider Ranjan Jayanathan Sells 65,598 SharesAugust 24, 2025 | americanbankingnews.comRussell Investments Group Ltd. Purchases 13,147 Shares of RadNet, Inc. $RDNTAugust 24, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Upgraded at Zacks ResearchAugust 22, 2025 | marketbeat.comCornelis Wesdorp Sells 1,500 Shares of RadNet (NASDAQ:RDNT) StockAugust 22, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCatalysts Align: Archer Beats Estimates, Delivers Aircraft to UAEBy Jeffrey Neal Johnson | August 13, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Oracle’s 2025 Rally Is Only Half Over: 5 Reasons WhyBy Thomas Hughes | August 11, 2025Can AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025NAKA, HIMS, GH, and RDNT Company DescriptionsGuardant Health NASDAQ:GH$67.42 +2.95 (+4.58%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$67.32 -0.10 (-0.15%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Hims & Hers Health NYSE:HIMS$42.36 -1.76 (-3.99%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$42.58 +0.23 (+0.53%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.KindlyMD NASDAQ:NAKA$5.44 -0.49 (-8.26%) As of 08/29/2025 04:00 PM EasternKindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.RadNet NASDAQ:RDNT$71.76 -0.03 (-0.04%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$70.96 -0.80 (-1.11%) As of 08/29/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
